Supporting study product use and accuracy in self-report in the iprex study: Next step counseling and neutral assessment

AIDS and Behavior

Volumn 16, Issue 5, 2012, Pages 1243-1259

  Amico, K R ^a,b   McMahan, Vanessa ^c   Goicochea, Pedro ^c   Vargas, Lorena ^d   Marcus, Julia L ^c   Grant, Robert M ^c,e   Liu, Albert ^f  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Applied Health Research   (United States)

^c GLADSTONE INSTITUTES   (United States)

^d Investigaciones Medicas en Salud   (Peru)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Department of Public Health ^*  (United States)

Author keywords

Adherence; Intervention; IPrEx; Neutral assessment; Next step counseling; PrEP; Self report

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ATTITUDE TO HEALTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTIVE COUNSELING; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FOLLOW UP; HOMOSEXUALITY; HUMAN; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEXUALITY; STANDARD; STATISTICS; TRANSSEXUALISM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DIRECTIVE COUNSELING; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; PATIENT ACCEPTANCE OF HEALTH CARE; PHOSPHONIC ACIDS; SELF REPORT; SEXUAL PARTNERS; TRANSSEXUALISM;

EID: 84863725804     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0182-5     Document Type: Article

References (28)

1. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24:621-35.
2. Abdool KQ, Abdool KSS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
3. Grant RM, Lama JR, Anderson PL, McMahan V, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. NEJM. 2010. doi:10.1056/NEJMoa1011205.
4. Baeten J, Celum C, on behalf of Partners PrEP Study Team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the partners PrEP study. In: 6th international AIDS Society conference on HIV pathogenesis treatment and prevention, Rome; 2011.
5. Thigpen MC, Kebaabetswa PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study.In: 6th international AIDS society conference on HIV pathogenesis treatment and prevention. Rome; 2011.
6. Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexporsure prophylaxis for HIV. AJPH. 2011;101(6):982-5.
7. Amico KR, Liu A, McMahan V et al. Adherence indicators and pre-exposure prophylaxis (PrEP) drug levels in the iPrEx study.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011.
8. Anderson PL, Lama JR, Buchbinder S et al. Interpreting detection rates of intracellular emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) in the iPrEx trial.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011.
9. Grant R, Lama J, Glidden D et al. Pre-exposure chemprophylaxis for prevention of HIV among trans-women and MSM: iPREx study.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011.
10. Vargas L, Amico KR, Goicochea P et al. Pill-taking support and assessment: Self reported perceptions of participants in a PrEP trial. International Association of Physicians in Adherence Care Conference. Miami, USA, 2010. [abstract # 62257].
11. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH: planning health promotion programs. An Intervention Mapping approach. 2nd edn. San Francisco, CA, Jossey-Bass; 2006.
12. Kok G, Schaalma H, Ruiter RA, van Empelen P, Brug J. Intervention mapping: protocol for applying health psychology theory to prevention programmes. J Health Psychol. 2004;9(1):85-98. (Pubitemid 38112062)
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009, Dec. Accessed 27 Feb 2012 from http://www.ispor.org/workpaper/FDA%20PRO%20Guidance.pdf.
14. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS and Behav. 2012. doi:10.1007/s10461-012-0172-7.
15. Fisher JD, Fisher WA, Amico KR, Harman JJ. An informationmotivation- behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462-73. (Pubitemid 44167248)
16. Fisher JD, Amico KR, Fisher WA, Harman JJ. The informationmotivation- behavioral skills model of antiretroviral adherence and its applications. Curr HIV/AIDS Rep. 2008;5(4):193-203.
17. Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6(4):177-86.
18. Fisher JD, Fisher WA, Cornman DH, Amico KR, Bryan A, Friedland GH. Clinician-delivered Intervention during routine clinical care reduces risky sexual behavior of HIV infected patients. J Acquir Immune Defic Syndr. 2006;41(1):44-52. (Pubitemid 41786018)
19. Rollnick S, Miller WR, Butler CC. Motivational Interviewing in Health Care: Helping Patients Change Behavior. New York: Guilford Press; 2008.
20. Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psych Bull. 1992;111(3):455-74.
21. Centers for Disease Control and Prevention. Morbidity and mortality weekly report (MMWR), Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. 2011, Jan 28; 60(03); 65-68. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm?s-cid=mm6003a1-w Accessed 25 Sept 2011.
22. Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep. 2010;7(4):201-9.
23. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk US populations: current considerations in light of new findings. AIDS Pt Care STDs. 2011;25(2):63-71.
24. Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5(4):186-92.
25. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J AIDS. 2006;41(3):285-97.
26. Centers for Disease Control and Prevention. Compendium of evidence-based HIV behavioral interventions: medication adherence chapter. http://www.cdc.gov/ hiv/topics/research/prs/ma-chapter.htm Accessed 25 Sept 2011.
27. de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impacts intervention effects in HAART adherence RCTs: a meta-analysis. Arch Intern Med. 2010;170(3):240-50.
28. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load-a meta-analytic review of randomized controlled trials. J AIDS. 2006;43:S23-S35. (Pubitemid 44885639)